Setting an appropriate reimbursement level for the Shockwave Medical, Inc. C2 coronary intravascular lithotripsy (IVL) device could pose a challenge for The US Center for Medicare and Medicaid, one reimbursement expert says.
CMS’s transactional pass-through (TPT) payment for the device began 1 July 2021 and is set to end in summer 2024....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?